Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs-Reference-Cited by-同舟云学术

Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs

Published:2014-11-19 Issue:2 Volume:20 Page:163-178
ISSN:1382-4147
Container-title:Heart Failure Reviews
language:en
Short-container-title:Heart Fail Rev

Author:

Castaño Adam,Drachman Brian M.,Judge Daniel,Maurer Mathew S.

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10741-014-9462-7.pdf

Reference112 articles.

1. Dharmarajan K, Maurer MS (2012) Transthyretin cardiac amyloidoses in older North Americans. J Am Geriatr Soc 60(4):765–774

2. Rapezzi C et al (2009) Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 120(13):1203–1212

3. Connors LH et al (2009) Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. Am Heart J 158(4):607–614

4. Jacobson DR et al (1996) Revised transthyretin Ile 122 allele frequency in African-Americans. Hum Genet 98(2):236–238

5. Hornsten R et al (2010) Heart complications in familial transthyretin amyloidosis: impact of age and gender. Amyloid 17(2):63–68

Cited by 196 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biotechnology Advances in Disease Treatment;International Encyclopedia of Public Health;2025

2. Transthyretin Amyloidosis: Role of oxidative stress and the beneficial implications of antioxidants and nutraceutical supplementation;Neurochemistry International;2024-10

3. Challenges in the approach to a patient with aortic stenosis and cardiac amyloidosis with ATTR mutation associated with negative scintigraphy - A case report;American Heart Journal Plus: Cardiology Research and Practice;2024-09

4. Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study;Journal of the Formosan Medical Association;2024-09

5. Transthyretin Stabilizer Therapy in Patients With Transthyretin Amyloid Cardiomyopathy: A Systematic Review and Meta-Analysis;American Journal of Therapeutics;2024-08-07